#Torrent Pharma share price today | Explore Tumblr posts and blogs

financesaathi · 2 months ago

Text

Top Stocks to Watch on September 27: Major Announcements Impacting the Market

In today’s stock market roundup for September 27, several key announcements and movements are expected to make an impact on trading strategies. Here are the stocks to keep an eye on:

NTPC: Joint Venture for Renewable Energy

NTPC has announced the formation of a joint venture with Mahatma Phule Renewable Energy for the development of 10 GW of renewable energy projects. This strategic partnership could significantly bolster NTPC’s commitment to sustainable energy. Investors are keen to watch the future implications of this massive expansion in the renewable energy sector, which could influence NTPC stock performance in the short and long term.

Torrent Pharma: Refuting Quality Concerns

Torrent Pharma has been in the spotlight recently after allegations of quality issues with their Shelcal 500 product. However, the company has officially refuted these claims, stating that the reports of failing quality tests are unfounded. While this may ease investor concerns, the market will closely follow any further developments related to Torrent Pharma.

Nuvama Wealth: Stake Sale

Nuvama Wealth is making waves with the news that Srcs, Edel Fin, and Ecap Eq will be selling a 6.4% stake through block deals at a floor price of ��6,445 per share. Stake sales like these often create a buzz in the market, and the impact on Nuvama's stock could be significant depending on how the sale progresses.

Union Bank: Strike Disruptions

Union Bank employees have announced plans to go on strike on September 27, which could potentially disrupt banking services. The strike is backed by 7% of the workforce, and this move may lead to some operational delays for the bank, affecting customers and possibly shaking investor confidence in Union Bank shares.

Get More Info : ABS marine share price

Website : https://financesaathi.com/

#Dindigul Farm ipo review #ABS marine share price #Financial News Today #Stock market masterclass

0 notes

newzzhub · 4 years ago

Photo

Torrent Pharma Surges 10% After Profit Rises 49% In June Quarter As of 10:42 am Torrent Pharma shares traded 9.2 per cent higher at Rs 2,661.10. Shares of Torrent Pharmaceuticals rose as much as 10 per cent to hit an intraday high of Rs 2,675.35 after its consolidated net profit in June quarter rose 49 per cent annually to Rs 321 crore.

#Torrent Pharma #Torrent Pharma earnings #Torrent Pharma Q1 #Torrent Pharma share price today #Torrent Pharma shares #Torrent Pharmaceuticals #Torrent Pharmaceuticals Q1 earnings #Torrent Pharmaceuticals shares #Torrent profit

0 notes

dianarusco · 3 years ago

Text

hives treatment Market Size, Development, Share and Forecast to 2026Including Covid19 Impact | Novartis AG, F. Hoffmann-La Roche Ltd, Elorac, GlaxoSmithKline PLC, CELLTRION INC, Teva Pharmaceutical Industries Ltd

The hives treatment market report has been prepared to bring about comprehensive analysis of the market structure along with forecast of the different segments and sub-segments of the market. The hives treatment market report has been formulated to bring about comprehensive analysis of the market structure along with forecast of the different segments and sub-segments of the market. Analysis of consumer needs by major regions, types, applications in Global market by considering the past, present and future state of the industry has been conducted. The report is prepared based on the market type, size of the organization, availability on-premises and the end-users’ organization type.

Global hives treatment market is expected to grow at a healthy CAGR in the forecast period of 2019-2026.

This hives treatment market research report is generated by using integrated approaches and latest technology for the best results. Analysis and estimation of important industry trends, market size, and market share are mentioned in this hives treatment report. Various trustworthy sources such as journals, websites, annual reports of the companies, and mergers are used for the gathering of data and information mentioned in this hives treatment report. This market research report is prepared by keeping in mind today’s business needs and advancements in technology. In no doubt, businesses will increase sustainability and profitability with this hives treatment market research report.

Get Sample PDF ofhives treatment Market Report (including COVID19 Impact Analysis)@ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hives-treatment-market

Market Drivers and Restraints:

Growing prevalence of urticaria worldwide is drive the market

Huge financial support to the researchers for developing novel intervention is boosting the market growth

High demand of disease specific novel treatment can also act as a market driver

Advancement in treatment and incorporation of novel formulation can improve the ease the pain of cold sores is also act as factors that drive the market

Patent expiry of branded drugs and introduction of generics is also acting as a challenging factor for the growth of this market

Low healthcare budget in some developing countries is hamper the market growth

Key Players: Global hives treatment Market

Novartis AG, F. Hoffmann-La Roche Ltd, Elorac, GlaxoSmithKline PLC, CELLTRION INC, Teva Pharmaceutical Industries Ltd, LANNETT, WOCKHARDT, Amneal Pharmaceuticals LLC, Aurobindo Pharma, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, ZydusCadila, Dr. Reddy’s Laboratories Ltd, Torrent Pharmaceuticals Ltd, Breckenridge Pharmaceutical, Inc and others.

MAJOR TOC OF THE REPORT

Chapter One: hives treatment Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global hives treatment Market Competition, by Players

Chapter Four: Global hives treatment Market Size by Regions

Chapter Five: Global hives treatment Market Revenue by Countries

Chapter Six: Global hives treatment Market Revenue by Type

Chapter Seven: Global hives treatment Market Revenue by Drugs

Chapter Eight: Global hives treatment Market Revenue by Route of Administration

Chapter Nine: Global hives treatment Market Revenue by End- Users

Chapter Ten: Global hives treatment Market Revenue by Distribution Channel

Chapter Eleven: Global hives treatment Market Revenue by Geography

Get Detail TOC@ https://www.databridgemarketresearch.com/toc/?dbmr=global-hives-treatment-market

Key Report Highlights

Comprehensive pricing analysis based on different product types and regional segments

Market size data in terms of revenue and sales volume

Deep insights about regulatory and investment scenarios of the global hives treatment Market

Analysis of market effect factors and their impact on the forecast and outlook of the global hives treatment Market

Key Questions Answered in Report:

What is the key to the hives treatment Market?

What will the hives treatment Market Demand and what will be Growth?

What are the latest opportunities for hives treatment Market in the future?

What are the strengths of the key players?

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-hives-treatment-market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]

Browse Related Reports@

Photoacoustic Tomography Market

Pharmacy Automation Market

PlexiformNeurofibromas Treatment Market

0 notes

viralafeed · 4 years ago

Text

STRIDES PHARMA SCIENCE Share Price Up by 5%; BSE HEALTHCARE Index Up 0.8%

Fri, 16 Apr 12:02 PM STRIDES PHARMA SCIENCE share price has zoomed 5% and is presently trading at Rs 898. Meanwhile, the BSE HEALTHCARE Index is at 22,828 (up 0.8%). Among the top Gainers in the BSE HEALTHCARE Index today is STRIDES PHARMA SCIENCE (up 5.1%). TORRENT PHARMA (down 0.1%) and J.B.CHEMICALS (down 0.2%) are among the top losers today. Over the last one year, STRIDES PHARMA SCIENCE has…

View On WordPress

0 notes

marketreasearch · 4 years ago

Text

Global Geriatric Medicines Market to Witness a Pronounce Growth During 2027

Global geriatric medicines market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. Emerging markets and huge investment in research and development are the factors responsible for the growth of this market.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-geriatric-medicines-market

Competitive Landscape and Global Geriatric Medicines Market Share Analysis

Global geriatric medicines market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to geriatric medicines market.

The major players covered in the global geriatric medicines market are Pfizer Inc, Otsuka Pharmaceutical Co., Ltd, AstraZeneca, Bristol-Myers Squibb Company, Allergan, Dr. Reddy's Laboratories Ltd, Pfizer Inc, Endo International plc, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Mylan N.V., Novartis AG, Lupin, Cipla Inc, Aurobindo Pharma, Torrent Pharmaceuticals Ltd, Sanofi, Merck & Co., Inc, Apotex Inc, Mayne Pharma Group Limited and others.

Patient Epidemiology Analysis

Global geriatric medicines market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Market Drivers and Restraints:

The growth of geriatric medicines market enhanced by the growing cases of orthopaedics diseases such as osteoporosis and arthritis, vulnerable aging population and rise in research and development activities conducted by many pharmaceuticals’ companies. In addition, increase patient awareness level, advances in the treatment options and adoption of sedentary life-style are some of the impacting factors for the demand of geriatric drugs. Nevertheless, product recalls coupled with high treatment cost are the factors that hinder the growth of this market.

Geriatric medicines are also termed as geriatrics is the study of medicine that specifically focuses on the diagnosis, promotion, treatment or disabilities and prevention of disease occur in the older patient.

Geriatric medicines market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Buy this Report (Can be used by entire organization across the globe + Downloadable and Printable PDF + 30 + Countries) @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-geriatric-medicines-market

Global Geriatric Medicines Market Scope and Market Size

Geriatric medicines market is segmented on the basis of indication, drug class, route of administration end-users and distribution channel.

On the basis of indication, the global geriatric medicines market is segmented into cardiovascular, arthritis, diabetes, neurological, cancer, osteoporosis, respiratory and others.

Based on drug class, the global geriatric medicines market is segmented into analgesic, antihypertensive, statins, antidiabetic, proton pump inhibitor, anticoagulant, antipsychotic and antidepressant and others.

Route of administration segment for global geriatric medicines market is categorized into oral, parenteral and others

On the basis of end-users, the global geriatric medicines market is segmented into hospitals, homecare, specialty clinics and others.

On the basis of distribution channel, the global geriatric medicines market has been bifurcated into hospital pharmacy, online pharmacy and retail pharmacy.

Global Geriatric Medicines Market Country Level Analysis

Global geriatric medicines market is analyzed and market size information is provided by country, indication, drug class, route of administration, end-users and distribution channel as referenced above.

The countries covered in the global geriatric medicines market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, in the Asia-Pacific, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

Based on geography, North America has been witnessing a positive growth for geriatric medicines market throughout the forecasted period owing to the high prevalence of chronic illness and increase in number of FDA approval drugs. Europe is considered a second largest growing regional segment due to the key marketed players and increases focuses on the mental health. Asia-Pacific leads the market due to the developing healthcare facilities, large number of generic manufacturer and rise in government initiatives and specialist communities.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Chapters to deeply display the Global Geriatric Medicines market.

Introduction about Geriatric Medicines

Geriatric Medicines Market Size (Sales) Market Share by Type (Product Category) in 2019

Geriatric Medicines Market by Application/End Users

Geriatric Medicines Sales (Volume) and Market Share Comparison by Applications

(2020-2027 ) table defined for each application/end-users

Geriatric Medicines Sales and Growth Rate (2020-2027)

Geriatric Medicines Competition by Players/Suppliers, Region, Type and Application

Geriatric Medicines (Volume, Value and Sales Price) table defined for each geographic region defined.

Geriatric Medicines Players/Suppliers Profiles and Sales Data ……………..

Additionally Company Basic Information, Manufacturing Base and Competitors list is being provided for each listed manufacturers

Market Sales, Revenue, Price and Gross Margin table for each product type which include , Product Type I, Product Type II & Product Type III

Geriatric Medicines Manufacturing Cost Analysis

Geriatric Medicines Key Raw Materials Analysis

Geriatric Medicines Chain, Sourcing Strategy and Downstream Buyers, Industrial Chain Analysis

Market Forecast (2020-2027)

……..and more in complete table of Contents

For More Insights Get Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-geriatric-medicines-market

Key questions answered in this report

What will the market size be in 2027 and what will the growth rate be

What are the key market trends?

What is driving Geriatric Medicines Market?

What are the challenges to market growth?

Who are the key vendors in Market space?

What are the key market trends impacting the growth of the Geriatric Medicines Market ?

What are the key outcomes of the five forces analysis of the Geriatric Medicines Market?

What are the market opportunities and threats faced by the vendors in the Geriatric Medicines market? Get in-depth details about factors influencing the market shares of the Americas, APAC, and EMEA?

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today! Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[email protected]

0 notes

boldlykeenblizzard · 5 years ago

Text

share market: Invest 10-20% now and wait for markets to move over next 3-4 sessions: Sudip Bandyopadhyay

There are those individual stocks which are looking right when it comes to valuation. What would you advise right now — buy this dip or stay clear of the market? Volatility is the order of the day and the extreme volatility which we have witnessed over the last five-seven days, not only in India but globally definitely is a cause of significant concern for the investors. The question is whether to start buying as far as the long- term investors are concerned.

The way we are advising investors is that there are lots of stocks which you wanted to buy but considering the high valuation, you did not venture into that. Now the valuations are looking really good compared with 15 days back. It is an excellent opportunity to start accumulating but the question is would you buy today or would you buy tomorrow or would you wait for it.

The way we are structuring this entire thing is we are saying that if you have money, invest maybe 10% to 20% and wait for the markets to move from here on over the next three-four trading sessions. You cannot catch the bottom and you are never sure whether this is the end of the market correction.

If you have identified a good business that you wanted to buy, why not buy it when it has come down by 20-30%? A stock like ICICI Bank has corrected significantly. It is a great opportunity to buy a bank like ICICI at current level when pretty much everything is gloom and doom as far as private sector banks are concerned.

Look at the entire FMCG pack. There has been a good amount of correction. We believe there are green shoots available as far as rural demand is concerned. Why not go and buy a Dabur or Marico. We have to start slowly moving back into the market. These are opportunities which the market gives once in a while. A long-term investor or somebody who is trying to build his portfolio has to start getting into the market now.

What have you made of the developments at YES Bank? As far as the bank is concerned, the developments over the last few days are looking positive. State Bank should be in a position to conclude very soon and if the moratorium is lifted by the end of this week, that will be excellent news. Now the question is valuation of the equity shares. Probably the market is not getting it right. I do not expect the valuation to be significantly higher than the par levels.

I am not sure whether the current market rate of around Rs 22-25, whatever it is quoting right now is an appropriate value for Yes Bank at this stage. If SBI comes in at par or close to par and the other investors come in at that rate, the market will witness one more round of selling to bring the value around that level.

Having said that, can State Bank value the bank at a double the par value which is about 20 bucks? I am not very sure considering the asset quality challenges and considering what has happened and considering the time it will take the bank to come back on rails. It is prudent to stay away from the counter. Yes, the speculators and the day traders will definitely trade and try to benefit but for an investor it is an absolute no, no.

Let us talk about Reliance for a moment. It is looking unsettled on the back of the Aramco deal looking a bit uncertain right now. On the other hand you have got the OMCs which did not react too well to the kind of recovering spike in crude? There are a couple of issues; one is that in the immediate future, a sudden crash in oil prices leads to inventory depreciation and the inventory valuation loss will probably get crystallized in case of some of these OMCs and even Reliance. Maybe, one needs to be a little careful as far as that inventory valuation part is concerned.

As far as Reliance standalone is concerned, the apprehensions and the corrections have been overdone. There are three businesses which the company runs predominantly now; one is the oil and gas piece, the second is the telecom and third is the retail. Yes, there is a petchem business also which is doing reasonably well. As far as oil and gas is concerned, there is volatility and because of what is happening, this Aramco deal may get delayed.

Structurally and fundamentally, if Aramco in principle agrees to acquire a stake in Reliance, I do not think the temporary price fluctuation will not change the contours of the deal though the timing may be shifting a bit. The question is Reliance has some amount of debt in the books and the market was expecting the reduction of the debt and that probably gets delayed.

We will have to wait and watch how things pan out as far as listing of the retail business is concerned. This is a fantastic business and the largest retail player in the country with shop level breakeven coming in. The other is over the monetisation of the telecom business over the next 12 to 18 months, which pieces of the telecom business would get monetised or investors come in.

The only question mark is over the debt reduction and the speed of the same. Otherwise all the businesses are fundamentally strong ad the price correction has been overdone. You can easily look at Rs 1,500 plus, the moment recovery sets in.

In some of the other names that have stood out, Asian Paints has been top of mind to day because it has managed to be the most resilient. But the question arises whether or not we will actually see multifold returns in some of these names that are actually working as safer bets right now? There are two things which come to my mind when we talk about the paint companies and you are absolutely right they have been performing much better than most of the other players in multiple other consumer related sectors. They have withstood the downturn in Indian economy very well. Also, the oil price coming down does give them cost benefit but that comes with a lag impact.

It is not that immediately Asian Paints will get the benefit, it will come with a lag. Maybe next quarter we will see the benefit if the oil price remains low. As far as the demand is concerned, yes, there has been reasonably good amount of work done by the paint companies and their demand has not shrunk the way other FMCG companies suffered.

We believe that the period of growth in spite of the overall economy not doing well is over. If the economy does not pick up or the construction sector, house building sector and the other related sectors where paints are required is not doing well on a consistent basis for a very long time, the paint companies will start showing the kind of fault lines in their armour and get into a bit of a challenge as far as their sales volume growth is concerned.

We have to be a little cautious. Oil price coming down is good news for them but the demand growth not happening either on account of coronavirus or the global growth slowing down, domestic growth not coming back would remain a matter of concern.

Pharmaceuticals is the other pocket that is finding favour and a lot of people who are of the opinion that it may make sense to not just venture into pure play pharma names but even some of the healthcare spaces as well, which for almost one year has been delivering on its earnings as well. Is that a space that interests you? Definitely. Pharma, healthcare, speciality chemicals and chemicals are the spaces which we believe should do well over a long period of time and definitely in the short to medium term. These are the stocks which one should try and accumulate. Since you asked pharma specifically, I will like to point out that we like domestic pharma companies in the sense companies which have a significant part of their sales in the domestic market.

Domestic pharma has been growing at 15% CAGR and Indian companies will benefit significantly out of this growth. A Torrent Pharma, Natco Pharma or most other companies which have got domestic exposure are our favourites at this stage. I am not saying companies with global exposure will not do well but there are elements of volatility attached with the US market and unfortunately we have to live with that.

If you have invested in a company with a significant exposure in the US, be prepared for volatility and it can be asymmetrical volatility. You cannot really plot that volatility on a graph and be assured. My advice to investors is focus on pharma companies with domestic focus and non-US markets. Apollo can definitely be looked at for the medium to long term. It is doing well and it is expected to do even better. The overhang of the promoter share pledge has got reduced significantly post the Apollo Munich deal.

We believe that it will not impact the company’s performance or the share market performance in the near future. As far as speciality chemicals and chemicals is concerned, the US China trade war as well as the coronavirus impact where the global procurers have realised that supply chain depends completely on China is not the thing to go ahead with.

Indian manufacturers will definitely get preference and we have excellent speciality chemical companies whether it is an Aarti Industries or a Nocil or Deepak Nitrite. One can look at buying these stocks at current levels with one year plus time horizon in mind.

if(geolocation && geolocation != 5 && (typeof skip == 'undefined' || typeof skip.fbevents == 'undefined')) { !function(f,b,e,v,n,t,s) {if(f.fbq)return;n=f.fbq=function(){n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}; if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version='2.0'; n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0]; s.parentNode.insertBefore(t,s)}(window, document,'script', 'https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '338698809636220'); fbq('track', 'PageView'); }

Source link

The post share market: Invest 10-20% now and wait for markets to move over next 3-4 sessions: Sudip Bandyopadhyay appeared first on Investium.

from Investium https://ift.tt/2W71cGn

#Investium

0 notes

ainvestops · 5 years ago

Text

share market: Invest 10-20% now and wait for markets to move over next 3-4 sessions: Sudip Bandyopadhyay

Source link

The post share market: Invest 10-20% now and wait for markets to move over next 3-4 sessions: Sudip Bandyopadhyay appeared first on Invest Ops.

from Invest Ops https://ift.tt/2U1lrD3

#Invest Ops

0 notes

eqtmonline03-blog · 6 years ago

Text

ADANI POWER Plunges by 6%; BSE POWER Index Down 0.1%

ADANI POWER share price has plunged 6% and is presently trading at Rs 31.

Meanwhile, the BSE POWER Index is at 1,994 (down 0.1%).

Among the top losers in the BSE POWER Index today is ADANI POWER (down 6.1%).

RELIANCE INFRA (up 3.0%) and SIEMENS (up 1.0%) are among the top gainers today.

Over the last one year, ADANI POWER has moved down from Rs 33 to Rs 31, registering a loss of Rs 2 (down 5.6%)..

The BSE POWER has moved down from 2,342 to 1,994, loss of 348 points (down 14.9%) during the last 12 months.

The top gainers among the BSE POWER Index stocks during this same period were ADANI TRANSMISSION (up 33.9%), TORRENT POWER LTD (up 14.2%) and KEC INTERNATIONAL (up 8.3%).

What About the Benchmark Indices?

The BSE Sensex is at 37,849 (up 0.4%). The top gainers among the BSE Sensex stocks today are HIND. UNILEVER (up 1.7%), M&M (up 1.3%) and YES BANK (up 1.0%). Other gainers include KOTAK MAH. BANK (up 1.0%) and SUN PHARMA (up 0.9%). The most traded stocks in the BSE Sensex are SBI and HDFC BANK.

In the meantime, NSE Nifty is at 11,423 (up 0.3%). HINDALCO (up 1.2%) is among the top gainers in NSE Nifty.

Over the last 12 months, the BSE Sensex has moved up from 32,274 to 37,849, registering a gain of 5,575 points (up 17.3%).

ADANI POWER Financial Update...

ADANI POWER net profit declined 49.8% YoY to Rs 6 billion for the quarter ended March 2018, compared to a loss of Rs 13 billion a year ago. Net Sales declined 16.1% to Rs 40.6 billion during the period as against Rs 48.4 billion in January-March 2017.

For the year ended March 2017, ADANI POWER reported 480.8% decrease in net profit to Rs 21.0 billion compared to net profit of Rs 5.5 billion during FY16.

Revenue of the company grew 10.8% to Rs 228 billion during FY17.

The current Price to earnings ratio of ADANI POWER, based on rolling 12 month earnings, stands at down 5.7x.

This article was originally published in English at www.equitymaster.com

Read the complete Indian stock market update. For the terms of use, go here.

0 notes

zoidresearch · 7 years ago

Text

Today’s Top Stocks In News | Market Update

Hello traders and investors. Here are the list of top stocks that are in news today:

Results today: Tata Consultancy Services, IndusInd Bank, Bajaj Corp, Shree Cements, 5paisa Capital, Alpha Hi-Tech Fuel, Hindustan Media Ventures, Sintex Plastics Technology, Suraj, Suryajyoti Spinning Mills, Websol Energy System

GE Power

The company Has been awarded a contract worth Rs 818.3 crore by Navayuga Engineering Company Limited to design, engineering, manufacturing, supply, erection, testing and commissioning of 12 numbers, 80 MW capacity vertical full Kaplan Turbine generator units

DCB Bank

The bank informed that a meeting of the board of directors will be held on Wednesday, January 17, 2018, to consider and approve the unaudited financial results (Provisional) for Q3 and the nine months ended December 31, 2017.

Can Fin Homes

The company has entered into a contract with 'Canara HSBC Oriental Bank of Commerce Life Insurance Company Limited' for carrying out the corporate agency business.

Bulge bracket private equity funds including TPG Capital Management, Bain Capital and Baring Private Equity Asia are in initial talks to buy state-run Canara Bank’s 30 percent stake in its listed housing finance subsidiary, Can Fin Homes, as the Bengaluru-based lender tries to improve its capital base, said an ET report.

Maruti Suzuki, Honda hikes prices by up to Rs 32,000

Various automakers including, Hyundai Motor India, Honda Cars, Mahindra & Mahindra have already announced to increase prices from this month. These companies are, however, yet to announce price increase for their respective vehicles.

Maruti Suzuki announced price increase ranging from Rs 1,700 to Rs 1,7000.

Pharma stocks will be in focus

Homegrown Aurobindo Pharma, Zydus Cadila, Torrent Pharma and Intas have expressed preliminary interest in buying the European generics business of Paris-headquartered pharma giant Sanofi as frenzied deal making continues in Big Pharma the world over in the new year, ET reported.

Tata Chemicals

Tata Chemicals on Wednesday said it has received approval from majority shareholders for sale of its Haldia fertiliser unit in West Bengal to Netherlands-based Indorama Holdings BV for Rs 375 crore.

DLF

The Supreme Court on Wednesday upheld the Kerala High Court order imposing a fine of Rs 1 crore on real estate major DLF for constructing around 180 luxury flats along the banks of eco-sensitive Chilavannur backwaters near Kochi in Kerala.

India Nippon Electricals

The company has been decided to convene a meeting of the board of directors on Monday the January 29 to consider payment of an interim dividend and sub-division of equity shares of the company. This proposal will be subject to the approval of the shareholders.

Bank of Baroda

India’s third-largest state-run lender is seeking to sell unit Nainital Bank as it sheds non-core assets to bolster its balance sheet, people familiar with the matter said, Mint reported.

ONGC

After a gap of over three-decade, state-owned Oil and Natural Gas Corp (ONGC) is set to open a new sedimentary basin in the country as it puts Kutch offshore on the oil and gas map of India.

Arihant Superstructures

Arihant Superstructures has received the approval of plan/commencement certificate for construction and implementation of its project named as 'Arihant Anaika Phase II' located at Taloja, Navi Mumbai

DIPAM on NMDC OFS -Government divested 2.52 percent stake in NMDC for Rs 1,200 crore -Government gets Rs 980 crore from non-retail investors & Rs 232 crore from the retail ones -Originally, NMDC OFS was meant to divest 1.5 percent government stake at Rs 153.50 per share -The OFS issue got oversubscribed three times the basic issue size -A discount of 5 percent on the cut-off price was offered to retail investors -Retail portion of NMDC OFS subscribed 4.39x (439 percent) -After the OFS, government shareholding in NMDC reduces to 72.42 percent from 74.94 percent

Other stocks and sectors in the news today: -Alok Industries says National Company Law Tribunal granted a 90-day extension in insolvency process -Orient Paper and Industries has ex-date for demerger today -Essar Steel bidders turn to SBI, ICICI Bank: Media Report -GMR to raise Rs 5,000 crore via airport business IPO: Media Report -Welspun Enterprises entered in a concession pact with Madhya Pradesh government for Dewas water supply project -Fitch assigns issuer default rating of BBB- to Power Grid -Welspun India's promoter sells stake worth Rs 350 crore -Bajaj Auto is confident of 8 percent jump in market share in 2 months Get more updated and profitable stock market trading tips by expert, click here https://goo.gl/9A28mr and get tips

#stock market trading tips #stocks in news #top stocks #market update

0 notes

viralafeed · 4 years ago

Text

DISHMAN CARBOGEN AMCIS Share Price Up by 5%; BSE HEALTHCARE Index Up 1.0%

Fri, 16 Apr 12:38 PM DISHMAN CARBOGEN AMCIS share price has zoomed 5% and is presently trading at Rs 123. Meanwhile, the BSE HEALTHCARE Index is at 22,828 (up 1.0%). Among the top Gainers in the BSE HEALTHCARE Index today are DISHMAN CARBOGEN AMCIS (up 5.5%) and STRIDES PHARMA SCIENCE (up 5.7%). SANOFI INDIA and TORRENT PHARMA (down 0.1%) are among the top losers today. Over the last one year,…

View On WordPress

0 notes

zoidresearch · 7 years ago

Text

Top Stocks In News | Share Market

Stocks in the news:

Tata Motors, MMTC, STC, RComm, AstraZeneca, AXISCADES, HFCL, Just Dial

Here are top stocks that are in news today:

Results today: BHEL, Cipla, Indian Overseas Bank, Manappuram Finance, VIP Industries, Orient Paper & Industries, Ballarpur Industries, Piramal Phytocare, Eimco Elecon, Balrampur Chini Mills, Vinati Organics, WABCO India, Butterfly Gandhimathi Appliances, Aditya Birla Capital, Indbank Merchant Banking Services, OCL India, Majesco, Prism Cement, Tata Coffee, NLC India, Prestige Estates, Asian Hotels (East), GSK Consumer Healthcare, Mandhana Industries, Filatex India, Huhtamaki PPL, Himatsingka Seide, Summit Securities, Tata Investment, Finolex Cables, Rossell India, Healthcare Global Enterprises, AVT Natural Products, Dhampur Sugar Mills, Adlabs Entertainment, Triveni Engineering, Future Retail, Monte Carlo Fashions, Jyothy Laboratories, Hexa Tradex, Dalmia Bharat, Pioneer Distilleries, Hindusthan National Glass, Jindal Saw, Johnson Controls, Hitachi Air Conditioning, RSWM, Apcotex Industries, Indoco Remedies, Teamlease Services, Magadh Sugar & Energy, Kolte-Patil Developers, Indo Rama Synthetics (India), Alembic Pharmaceuticals, Antarctica, Essel Propack, Thermax, Liberty Shoes, GTL, STI India, Mirza International, Healthcare Global Enterprises, Polaris Consulting, L&T Technology, Himachal Futuristic Communications, DCM Shriram

Torrent power Q2

Revenue at 2915 cr vs Ambit est at 2650 cr EBITDA at 838 cr vs est 850 cr Margin at 28.7% vs est 32% margin (PY : 24.5%) PAT at 321 cr vs est 307 cr Fuel cost at 794 cr v s 732 cr Fin cost down at 213 cr vs 264 cr

GTPL Hathway Q2FY18-YoY

Revenue up 22% at 181cr vs 148cr EBITDA up 16% at 56.8cr vs 49cr OPM at 31.3% vs 33.1% PAT up 53% at 11.7cr vs 7.6cr PAT higher due to exceptional profit of 4cr

Jaiprakash Power Ventures Q2FY18- YOY

Revenue up 25% at 825cr EBITDA up 9% at 302cr Margins down 540 bps at 36.6% Loss at at 156cr vs 161cr

Gujarat Industries Power Q2FY18- YOY

Revenue up 3% at 323cr EBITDA up 29% at 118.8cr Margins up 760 bps at 36.8% PAT up 6% at 53.3cr Base qtr had an other income of 20cr

Gujarat Gas Q2 QoQ

Revenue down 6% at 1430cr EBITDA down 24% at 202.5cr Margins down 350 bps at 14.2% PAT down 41% at 61cr

Bharat Seats Q2FY18 YoY

Revenue up 19% at 259cr EBITDA up 96% at 20.6cr Margins up 310 bps at 7.9% PAT at 10.2cr vs 3.5cr

AstraZeneca Pharma India Q2FY18 YoY

Revenue up 18% at 164cr EBITDA at 35.4cr vs 2.8cr Margins 21.6% vs 2% PAT at 27.cr vs 0.8cr Rev up 18% at but expenses down 6% leads to better results

Gulf Oil Lubricants Q2

Net Profit At `40.41 Cr Vs `29.28 Cr (YoY) Revenue (GU)22.5% At `322.9 Cr Vs `263.5 Cr (YoY) EBITDA (GU)44.2% At `62.28 Cr Vs `43.20 Cr (YoY) EBITDA Margin At 19.29% Vs 16.39% (YoY)

L&T Infotech

Net Profit (GU)4% At `273 Cr Vs `267.2 Cr (QoQ) Revenue (GU)4.8% At `1,750.8 Cr Vs `1,670 Cr (QoQ) EBITDA (RD)5.4% At `294.20 Cr Vs `279.1 Cr (YoY) EBITDA Margin At 16.8% Vs 16.7% (YoY)

Narayana Hrudayalaya Q2

Net Profit At `16.5 Cr Vs `26.5 Cr (YoY) Revenue At `559.2 Cr Vs `487.4 Cr (YoY

Just Dial Q2

Net Profit (RD)1.8% At `37.5 Cr Vs `38.2 Cr (QoQ) Revenue (GU)2.3% At `194.5 Cr Vs `190 Cr (QoQ) EBITDA (GU)21.9% At `39.6 Cr Vs `32.5 Cr (QoQ) EBITDA Margin At 20.4% Vs 17.1% (QoQ)

October Auto Sales: Tata Motors

JLR UK Sales Down 17.7% At 7,097 Units Vs 8,626 Units (YoY) Jaguar UK Sales Down 38.7% At 1,827 Units Vs 2,981 Units (YoY) Land Rover Sales Down 6.6% At 5,270 Units Vs 5,645 Units (YoY)

Narayana Hrudayalaya

Signs Pact To Buyback 71.4% Shrhlding In Health City Cayman Islands Stake In Health City Cayman Islands Held By Ascension Health Ventures To Make Health City Cayman Islands A 100% Step-down Subsidiary Of Co

Cabinet To Take Final Call On Commerce Min Proposal For STC-MMTC Merger Commerce Min Has Taken Expert Opinion On STC-MMTC Merger Proposal Could Take 6-8 Months For STC-MMTC Merger Process To Be Completed STC & MMTC Merger To Create A Stronger India-based Intl Trading Co

Govt Official To CNBC-TV18

New India Assurance Issue Price Approved At `800/Share Alternate Mechanism Headed By FM Gives Nod To NIA Issue Price At `800 NIA Issue Oversubscribed 1.15 Times At Higher End Of `772-800/Share Govt To Receive Around `7,500 Cr From NIA IPO; Total Proceeds At `9,467 Cr Subscribe for Intraday trading tips, on Equity market by experts here https://goo.gl/9A28mr

#intraday trading tips #top stocks

0 notes